{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:40:42Z","timestamp":1773362442985,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018573","name":"Istanbul Medeniyet University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018573","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Gout and rheumatoid arthritis (RA) are distinct disorders, but both of these inflammatory arthropaties are associated with a relatively similar risk of atherosclerotic cardiovascular disease. We aimed to assess carotid intima-media thickness (CIMT), flow-mediated vasodilatation (FMD) and coronary flow reserve (CFR) in both disorders to understand and compare the extent of vascular damage. Patients with recently diagnosed gout (<jats:italic>n<\/jats:italic>\u2009=\u200930) and RA (<jats:italic>n<\/jats:italic>\u2009=\u200940) without previous cardiovascular disease were included to the present study, and 45 healthy volunteers served as controls. All participants underwent ultrasonographic examinations to measure CIMT, FMD and CFR. In unadjusted analysis, both gout and RA were associated with a significantly higher CIMT and significantly lower CFR as compared to controls, while FMD was only lower in the gout group. After adjustment, there was a significantly higher odds ratio (OR) for CIMT (OR:7.02, 95%CI:2.45\u201320.58 for gout and OR:2.86, 95%CI:1.27\u20136.57 for RA) and a lower OR for CFR (OR:0.21, 95%CI:0.08\u20130.55 for gout and OR:0.17, 95%CI:0.07\u20130.45 for RA) in both groups, while only gout patients had a lower OR for FMD (OR:0.21, 95%CI:0.08\u20130.55). There were no significant differences or evidence of a difference between gout and RA patients for CIMT, FMD or CFR. Gout and RA are associated with a similar degree of vascular damage, which may explain the similar incidence of atherosclerotic cardiovascular disease in both diseases.<\/jats:p>\n          <jats:p>\n            <jats:bold>Graphical Abstract<\/jats:bold>\n          <\/jats:p>","DOI":"10.1007\/s00296-025-05868-6","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T02:18:16Z","timestamp":1745374696000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Gout and rheumatoid arthritis are associated with subclinical vascular damage, reduced brachial vasoreactivity and coronary microvascular dysfunction: a case-control study"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8498-4179","authenticated-orcid":false,"given":"O\u011fuz","family":"Konal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0974-8096","authenticated-orcid":false,"given":"Furkan","family":"B\u00f6len","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6738-266X","authenticated-orcid":false,"given":"Tolga Sinan","family":"G\u00fcven\u00e7","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6887-1801","authenticated-orcid":false,"given":"\u00d6zlem","family":"Pehlivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6286-3632","authenticated-orcid":false,"given":"Sevilay","family":"Bat\u0131bay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4472-4847","authenticated-orcid":false,"given":"Fatma Bet\u00fcl","family":"\u00d6zcan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3771-4114","authenticated-orcid":false,"given":"Ay\u015fe","family":"Paral\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1212-7127","authenticated-orcid":false,"given":"Feyza","family":"Aksu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8094-7402","authenticated-orcid":false,"given":"\u015eeref","family":"Kul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7417-4001","authenticated-orcid":false,"given":"Mustafa","family":"\u00c7al\u0131\u015fkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"5868_CR1","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41584-024-01137-1","volume":"20","author":"MP Leask","year":"2024","unstructured":"Leask MP, Cri\u0219an TO, Ji A, Matsuo H, K\u00f6ttgen A, Merriman TR (2024) The pathogenesis of gout: molecular insights from genetic, epigenomic and transcriptomic studies. Nat Rev Rheumatol 20:510\u2013523. https:\/\/doi.org\/10.1038\/s41584-024-01137-1","journal-title":"Nat Rev Rheumatol"},{"key":"5868_CR2","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1161\/ATVBAHA.119.313224","volume":"40","author":"Y Kimura","year":"2020","unstructured":"Kimura Y, Yanagida T, Onda A, Tsukui D, Hosoyamada M, Kono H (2020) Soluble uric acid promotes atherosclerosis via AMPK (AMP-Activated protein Kinase)-Mediated inflammation. Arterioscler Thromb Vasc Biol 40:570\u2013582. https:\/\/doi.org\/10.1161\/ATVBAHA.119.313224","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"5868_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41392-022-00955-7","volume":"7","author":"P Kong","year":"2022","unstructured":"Kong P, Cui ZY, Huang XF, Zhang DD, Guo RJ, Han M (2022) Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. Signal Transduct Target Ther 7:131. https:\/\/doi.org\/10.1038\/s41392-022-00955-7","journal-title":"Signal Transduct Target Ther"},{"key":"5868_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jjcc.2020.12.013","volume":"78","author":"Y Saito","year":"2021","unstructured":"Saito Y, Tanaka A, Node K, Kobayashi Y (2021) Uric acid and cardiovascular disease: A clinical review. J Cardiol 78:51\u201357. https:\/\/doi.org\/10.1016\/j.jjcc.2020.12.013","journal-title":"J Cardiol"},{"key":"5868_CR5","doi-asserted-by":"publisher","first-page":"e156","DOI":"10.1016\/S2665-9913(23)00338-7","volume":"6","author":"LD Ferguson","year":"2024","unstructured":"Ferguson LD, Molenberghs G, Verbeke G, Rahimi K, Rao S, McInnes IB et al (2024) Gout and incidence of 12 cardiovascular diseases: a case-control study including 152\u2008663 individuals with gout and 709\u2008981 matched controls. Lancet Rheumatol 6:e156\u2013e167. https:\/\/doi.org\/10.1016\/S2665-9913(23)00338-7","journal-title":"Lancet Rheumatol"},{"key":"5868_CR6","doi-asserted-by":"publisher","unstructured":"Lee TS, Lu TM, Chen CH, Guo BC, Hsu CP (2021) Hyperuricemia induces endothelial dysfunction and accelerates atherosclerosis by disturbing the asymmetric dimethylarginine\/dimethylarginine dimethylaminotransferase 2 pathway. Redox Biol. 2021; 46:102108. https:\/\/doi.org\/10.1016\/j.redox.2021.102108","DOI":"10.1016\/j.redox.2021.102108"},{"key":"5868_CR7","doi-asserted-by":"publisher","unstructured":"Strandberg TE, Kovanen PT Coronary artery disease: \u2018gout\u2019 in the artery? Eur Heart J 42:2761\u20132764. https:\/\/doi.org\/10.1093\/eurheartj\/ehab276","DOI":"10.1093\/eurheartj\/ehab276"},{"key":"5868_CR8","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1161\/HYPERTENSIONAHA.122.19247","volume":"79","author":"V Nardi","year":"2022","unstructured":"Nardi V, Franchi F, Prasad M, Fatica EM, Alexander MP, Bois MC et al (2022) Uric acid expression in carotid atherosclerotic plaque and serum uric acid are associated with cerebrovascular events. Hypertension 79:1814\u20131823. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.122.19247","journal-title":"Hypertension"},{"key":"5868_CR9","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.numecd.2023.11.019","volume":"34","author":"K Si","year":"2024","unstructured":"Si K, Chi J, Xu L, Dong B, Huang Y, Zhang H et al (2024) Tophi and carotid atherosclerosis in gout patients: role of insulin resistance. Nutr Metab Cardiovasc Dis 34:1134\u20131141. https:\/\/doi.org\/10.1016\/j.numecd.2023.11.019","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"5868_CR10","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3899\/jrheum.2023-0334","volume":"51","author":"LJ O\u2019Neil","year":"2024","unstructured":"O\u2019Neil LJ, Alp\u00edzar-Rodr\u00edguez D, Deane KD (2024) Rheumatoid arthritis: the continuum of disease and strategies for prediction, early intervention, and prevention. J Rheumatol 51:337\u2013349. https:\/\/doi.org\/10.3899\/jrheum.2023-0334","journal-title":"J Rheumatol"},{"key":"5868_CR11","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1136\/heartjnl-2019-316193","volume":"106","author":"E Nikiphorou","year":"2020","unstructured":"Nikiphorou E, de Lusignan S, Mallen CD, Khavandi K, Bedarida G, Buckley CD et al (2020) Cardiovascular risk factors and outcomes in early rheumatoid arthritis: a population-based study. Heart 106:1566\u20131572. https:\/\/doi.org\/10.1136\/heartjnl-2019-316193","journal-title":"Heart"},{"key":"5868_CR12","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1007\/s00296-023-05405-3","volume":"43","author":"S Mathieu","year":"2023","unstructured":"Mathieu S, Lambert C, Fayet F, Couderc M, Beauger M, Malochet S et al (2023) Comparison of the cardiovascular risk profile of rheumatoid arthritis versus hand osteoarthritis patients. Rheumatol Int 43:2065\u20132072. https:\/\/doi.org\/10.1007\/s00296-023-05405-3","journal-title":"Rheumatol Int"},{"key":"5868_CR13","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1016\/S2665-9913(20)30221-6","volume":"3","author":"R Hansildaar","year":"2021","unstructured":"Hansildaar R, Vedder D, Baniaamam M, Tausche AK, Gerritsen M, Nurmohamed MT (2021) Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout. Lancet Rheumatol 3:e58\u2013e70. https:\/\/doi.org\/10.1016\/S2665-9913(20)30221-6","journal-title":"Lancet Rheumatol"},{"key":"5868_CR14","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd et al (2010) 2010 Rheumatoid arthritis classification criteria: an American college of rheumatology\/european league against rheumatism collaborative initiative. Ann Rheum Dis 69:1580\u20131588. https:\/\/doi.org\/10.1136\/ard.2010.138461","journal-title":"Ann Rheum Dis"},{"key":"5868_CR15","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1002\/art.39254","volume":"67","author":"T Neogi","year":"2015","unstructured":"Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D et al (2015) 2015 Gout classification criteria: an American college of rheumatology\/european league against rheumatism collaborative initiative. Arthritis Rheumatol 67:2557\u20132568. https:\/\/doi.org\/10.1002\/art.39254","journal-title":"Arthritis Rheumatol"},{"key":"5868_CR16","doi-asserted-by":"publisher","unstructured":"Wigerblad G, Kaplan MJ (2023) Neutrophil extracellular traps in systemic autoimmune and autoinflammatory diseases. Nat Rev Immunol 2023 23:274\u2013288. https:\/\/doi.org\/10.1038\/s41577-022-00787-0","DOI":"10.1038\/s41577-022-00787-0"},{"key":"5868_CR17","doi-asserted-by":"publisher","first-page":"117473","DOI":"10.1016\/j.atherosclerosis.2024.117473","volume":"391","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, Wang T, Yang Y, Wang Z, Chen X, Wang L et al (2024) Low shear stress exacerbates atherosclerosis by inducing the generation of neutrophil extracellular traps via Piezo1-mediated mechanosensation. Atherosclerosis 391:117473. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.117473","journal-title":"Atherosclerosis"},{"key":"5868_CR18","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.4049\/jimmunol.1701382","volume":"200","author":"SM Chatfield","year":"2018","unstructured":"Chatfield SM, Grebe K, Whitehead LW, Rogers KL, Nebl T, Murphy JM, Wicks IP (2018) Monosodium urate crystals generate Nuclease-Resistant neutrophil extracellular traps via a distinct molecular pathway. J Immunol 200:1802\u20131816. https:\/\/doi.org\/10.4049\/jimmunol.1701382","journal-title":"J Immunol"},{"key":"5868_CR19","doi-asserted-by":"publisher","first-page":"140","DOI":"10.4078\/jrd.2022.29.3.140","volume":"29","author":"SK Kim","year":"2022","unstructured":"Kim SK (2022) The mechanism of the NLRP3 inflammasome activation and pathogenic implication in the pathogenesis of gout. J Rheum Dis 29:140\u2013153. https:\/\/doi.org\/10.4078\/jrd.2022.29.3.140","journal-title":"J Rheum Dis"},{"key":"5868_CR20","doi-asserted-by":"publisher","first-page":"443","DOI":"10.5551\/jat.RV17001","volume":"24","author":"T Karasawa","year":"2017","unstructured":"Karasawa T, Takahashi M (2017) Role of NLRP3 inflammasomes in atherosclerosis. J Atheroscler Thromb 24:443\u2013451. https:\/\/doi.org\/10.5551\/jat.RV17001","journal-title":"J Atheroscler Thromb"},{"key":"5868_CR21","doi-asserted-by":"publisher","first-page":"931690","DOI":"10.3389\/fimmu.2022.931690","volume":"13","author":"H Yin","year":"2022","unstructured":"Yin H, Liu N, Sigdel KR, Duan L (2022) Role of NLRP3 inflammasome in rheumatoid arthritis. Front Immunol 13:931690. https:\/\/doi.org\/10.3389\/fimmu.2022.931690","journal-title":"Front Immunol"},{"key":"5868_CR22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00296-023-05501-4","volume":"44","author":"V Mihaylova","year":"2024","unstructured":"Mihaylova V, Kazakova M, Batalov Z, Karalilova R, Batalov A, Sarafian V (2024) JAK inhibitors improve ATP production and mitochondrial function in rheumatoid arthritis: a pilot study. Rheumatol Int 44:57\u201365. https:\/\/doi.org\/10.1007\/s00296-023-05501-4","journal-title":"Rheumatol Int"},{"key":"5868_CR23","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13075-016-1012-3","volume":"18","author":"Y Zamudio-Cuevas","year":"2016","unstructured":"Zamudio-Cuevas Y, Mart\u00ednez-Flores K, Fern\u00e1ndez-Torres J, Loissell-Baltazar YA, Medina-Luna D, L\u00f3pez-Macay A et al (2016) Monosodium urate crystals induce oxidative stress in human synoviocytes. Arthritis Res Ther 18:117. https:\/\/doi.org\/10.1186\/s13075-016-1012-3","journal-title":"Arthritis Res Ther"},{"key":"5868_CR24","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1111\/bph.13828","volume":"175","author":"Q Chen","year":"2018","unstructured":"Chen Q, Wang Q, Zhu J, Xiao Q, Zhang L (2018) Reactive oxygen species: key regulators in vascular health and diseases. Br J Pharmacol 175:1279\u20131292. https:\/\/doi.org\/10.1111\/bph.13828","journal-title":"Br J Pharmacol"},{"key":"5868_CR25","doi-asserted-by":"publisher","first-page":"e002270","DOI":"10.1161\/JAHA.115.002270","volume":"4","author":"Y Matsuzawa","year":"2015","unstructured":"Matsuzawa Y, Kwon TG, Lennon RJ, Lerman LO, Lerman A (2015) Prognostic value of Flow-Mediated vasodilation in brachial artery and fingertip artery for cardiovascular events: A systematic review and Meta-Analysis. J Am Heart Assoc 4:e002270. https:\/\/doi.org\/10.1161\/JAHA.115.002270","journal-title":"J Am Heart Assoc"},{"key":"5868_CR26","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1161\/CIRCULATIONAHA.120.046361","volume":"142","author":"P Willeit","year":"2020","unstructured":"Willeit P, Tschiderer L, Allara E, Reuber K, Seekircher L, Gao L et al (2020) Carotid Intima-Media thickness progression as surrogate marker for cardiovascular risk: Meta-Analysis of 119 clinical trials involving 100 667 patients. Circulation 142:621\u2013642. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.046361","journal-title":"Circulation"},{"key":"5868_CR27","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1093\/eurheartj\/ehab775","volume":"43","author":"MA Kelshiker","year":"2022","unstructured":"Kelshiker MA, Seligman H, Howard JP, Rahman H, Foley M, Nowbar AN et al (2022) Coronary flow reserve and cardiovascular outcomes: a systematic review and meta-analysis. Eur Heart J 43:1582\u20131593. https:\/\/doi.org\/10.1093\/eurheartj\/ehab775","journal-title":"Eur Heart J"},{"key":"5868_CR28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jbspin.2015.12.003","volume":"84","author":"HJ Janssens","year":"2017","unstructured":"Janssens HJ, Arts PG, Schalk BW, Biermans MC (2017) Gout and rheumatoid arthritis, both to keep in Mind in cardiovascular risk management: A primary care retrospective cohort study. Joint Bone Spine 84:59\u201364. https:\/\/doi.org\/10.1016\/j.jbspin.2015.12.003","journal-title":"Joint Bone Spine"},{"key":"5868_CR29","doi-asserted-by":"publisher","first-page":"858","DOI":"10.3899\/jrheum.170555","volume":"45","author":"IJM Disveld","year":"2018","unstructured":"Disveld IJM, Fransen J, Rongen GA, Kienhorst LBE, Zoakman S, Janssens HJEM, Janssen M (2018) Crystal-proven gout and characteristic gout severity factors are associated with cardiovascular disease. J Rheumatol 45:858\u2013863. https:\/\/doi.org\/10.3899\/jrheum.170555","journal-title":"J Rheumatol"},{"key":"5868_CR30","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s13075-020-02339-0","volume":"22","author":"T Fatima","year":"2020","unstructured":"Fatima T, Nilsson PM, Turesson C, Dehlin M, Dalbeth N, Jacobsson LTH, Kapetanovic MC (2020) The absolute risk of gout by clusters of gout-associated comorbidities and lifestyle factors-30 years follow-up of the Malm\u00f6 preventive project. Arthritis Res Ther 22:244","journal-title":"Arthritis Res Ther"},{"key":"5868_CR31","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","volume":"61","author":"SM Nidorf","year":"2013","unstructured":"Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL (2013) Low-dose Colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 61:404\u2013410. https:\/\/doi.org\/10.1016\/j.jacc.2012.10.027","journal-title":"J Am Coll Cardiol"},{"key":"5868_CR32","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","volume":"381","author":"JC Tardif","year":"2019","unstructured":"Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP et al (2019) Efficacy and safety of Low-Dose Colchicine after myocardial infarction. N Engl J Med 381:2497\u20132505. https:\/\/doi.org\/10.1056\/NEJMoa1912388","journal-title":"N Engl J Med"},{"key":"5868_CR33","doi-asserted-by":"publisher","first-page":"101191","DOI":"10.1016\/j.ijcha.2023.101191","volume":"45","author":"MU Siddiqui","year":"2023","unstructured":"Siddiqui MU, Junarta J, Sathyanarayanan S, Kochar K, Ullah W, Fischman DL (2023) Risk of coronary artery disease in patients with gout on treatment with Colchicine: A systematic review and meta-analysis. Int J Cardiol Heart Vasc 45:101191. https:\/\/doi.org\/10.1016\/j.ijcha.2023.101191","journal-title":"Int J Cardiol Heart Vasc"},{"key":"5868_CR34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13075-020-02260-6","volume":"22","author":"M Toprover","year":"2020","unstructured":"Toprover M, Shah B, Oh C, Igel TF, Romero AG, Pike VC et al (2020) Initiating guideline-concordant gout treatment improves arterial endothelial function and reduces intercritical inflammation: a prospective observational study. Arthritis Res Ther 22:169. https:\/\/doi.org\/10.1186\/s13075-020-02260-6","journal-title":"Arthritis Res Ther"},{"key":"5868_CR35","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41440-022-01116-7","volume":"46","author":"J Naganuma","year":"2023","unstructured":"Naganuma J, Sakuma M, Kitahara K, Kato T, Yokomachi J, Yamauchi F et al (2023) Optimal uric acid reduction to improve vascular endothelial function in patients with chronic heart failure complicated by hyperuricemia. Hypertens Res 46:688\u2013696. https:\/\/doi.org\/10.1038\/s41440-022-01116-7","journal-title":"Hypertens Res"},{"key":"5868_CR36","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0140-6736(22)01657-9","volume":"400","author":"IS Mackenzie","year":"2022","unstructured":"Mackenzie IS, Hawkey CJ, Ford I, Greenlaw N, Pigazzani F, Rogers A et al (2022) Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Lancet 400:1195\u20131205. https:\/\/doi.org\/10.1016\/S0140-6736(22)01657-9","journal-title":"Lancet"},{"key":"5868_CR37","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","volume":"378","author":"WB White","year":"2018","unstructured":"White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A et al (2018) Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 378:1200\u20131210. https:\/\/doi.org\/10.1056\/NEJMoa1710895","journal-title":"N Engl J Med"},{"key":"5868_CR38","doi-asserted-by":"publisher","first-page":"e24579","DOI":"10.1097\/MD.0000000000024579","volume":"100","author":"KJ Sun","year":"2021","unstructured":"Sun KJ, Liu LL, Hu JH, Chen YY, Xu DY (2021) Methotrexate can prevent cardiovascular events in patients with rheumatoid arthritis: an updated meta-analysis. Med (Baltim) 100:e24579. https:\/\/doi.org\/10.1097\/MD.0000000000024579","journal-title":"Med (Baltim)"},{"key":"5868_CR39","doi-asserted-by":"publisher","first-page":"6627","DOI":"10.1038\/s41598-021-86128-y","volume":"11","author":"S Thanigaimani","year":"2021","unstructured":"Thanigaimani S, Phie J, Krishna SM, Moxon J, Golledge J (2021) Effect of disease modifying anti-rheumatic drugs on major cardiovascular events: a meta-analysis of randomized controlled trials. Sci Rep 11:6627. https:\/\/doi.org\/10.1038\/s41598-021-86128-y","journal-title":"Sci Rep"},{"key":"5868_CR40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/art.41095","volume":"72","author":"JT Giles","year":"2020","unstructured":"Giles JT, Sattar N, Gabriel S, Ridker PM, Gay S, Warne C et al (2020) Cardiovascular safety of Tocilizumab versus etanercept in rheumatoid arthritis: A randomized controlled trial. Arthritis Rheumatol 72:31\u201340. https:\/\/doi.org\/10.1002\/art.41095","journal-title":"Arthritis Rheumatol"},{"key":"5868_CR41","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/art.38894","volume":"67","author":"A Souto","year":"2015","unstructured":"Souto A, Salgado E, Maneiro JR, Mera A, Carmona L, G\u00f3mez-Reino JJ (2015) Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and Tofacitinib in randomized clinical trials: a systematic review and meta-analysis. Arthritis Rheumatol 67:117\u2013127. https:\/\/doi.org\/10.1002\/art.38894","journal-title":"Arthritis Rheumatol"},{"key":"5868_CR42","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1056\/NEJMoa1809798","volume":"380","author":"PM Ridker","year":"2019","unstructured":"Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E et al (2019) Low-Dose methotrexate for the prevention of atherosclerotic events. N Engl J Med 380:752\u2013762. https:\/\/doi.org\/10.1056\/NEJMoa1809798","journal-title":"N Engl J Med"},{"key":"5868_CR43","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s10067-023-06505-y","volume":"42","author":"B Abdulmajid","year":"2023","unstructured":"Abdulmajid B, Blanken AB, van Geel EH, Daams JG, Nurmohamed MT (2023) Effect of TNF inhibitors on arterial stiffness and intima media thickness in rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol 42:999\u20131011. https:\/\/doi.org\/10.1007\/s10067-023-06505-y","journal-title":"Clin Rheumatol"},{"key":"5868_CR44","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00296-019-04503-5","volume":"40","author":"L D\u00e1vida","year":"2020","unstructured":"D\u00e1vida L, Pongr\u00e1cz V, Mohamed EA, Szamosi S, Sz\u00fccs G, V\u00e1ncsa A et al (2020) A prospective, longitudinal monocentric study on laser doppler imaging of microcirculation: comparison with macrovascular pathophysiology and effect of adalimumab treatment in early rheumatoid arthritis. Rheumatol Int 40:415\u2013424. https:\/\/doi.org\/10.1007\/s00296-019-04503-5","journal-title":"Rheumatol Int"},{"key":"5868_CR45","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.mvr.2014.08.003","volume":"97","author":"Z Caliskan","year":"2015","unstructured":"Caliskan Z, Gokturk HS, Caliskan M, Gullu H, Ciftci O, Ozgur GT et al (2015) Impaired coronary microvascular and left ventricular diastolic function in patients with inflammatory bowel disease. Microvasc Res 97:25\u201330. https:\/\/doi.org\/10.1016\/j.mvr.2014.08.003","journal-title":"Microvasc Res"},{"key":"5868_CR46","doi-asserted-by":"publisher","first-page":"104458","DOI":"10.1016\/j.mvr.2022.104458","volume":"146","author":"S Kul","year":"2023","unstructured":"Kul S, Caliskan Z, Guvenc TS, Celik FB, Sarmis A, Atici A et al (2023) Gut microbiota-derived metabolite trimethylamine N-oxide and biomarkers of inflammation are linked to endothelial and coronary microvascular function in patients with inflammatory bowel disease. Microvasc Res 146:104458. https:\/\/doi.org\/10.1016\/j.mvr.2022.104458","journal-title":"Microvasc Res"},{"key":"5868_CR47","doi-asserted-by":"publisher","first-page":"100393","DOI":"10.1016\/j.ahjo.2024.100393","volume":"41","author":"T \u0130rgi","year":"2024","unstructured":"\u0130rgi T, Baycan \u00d6F, G\u00fcven\u00e7 TS, \u00d6zcan FB, At\u0131c\u0131 A, Y\u0131lmaz Y, \u00c7ali\u015fkan M (2024) Concomitant amyloidosis is the primary cause of endothelial and coronary microvascular dysfunction in carpal tunnel syndrome. Am Heart J Plus 41:100393. https:\/\/doi.org\/10.1016\/j.ahjo.2024.100393","journal-title":"Am Heart J Plus"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-05868-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-025-05868-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-05868-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T20:02:50Z","timestamp":1758052970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-025-05868-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":47,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["5868"],"URL":"https:\/\/doi.org\/10.1007\/s00296-025-05868-6","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"assertion":[{"value":"7 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised due incorrect affiliation of the author Sevilay Batibay. Now, it has been updated.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with 1964 Declaration of Helsinki and its subsequent revisions. Patients gave their written informed consent prior to inclusion, and the study was approved by a local ethics committee (Medeniyet University Clinical Research Ethics Committee, Decision Date: 24.05.2023, Document No: 2023\/0334).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The data that support the findings of this study are available from the corresponding author (MC), upon reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Open data sharing"}},{"value":"No editorial support from professional agencies or AI support was used for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Editing support and use of AI"}},{"value":"All authors declare that they have no conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"117"}}